Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia
Abstract
Quizartinib improved outcome compared to chemotherapy in the QuANTUM-R study (median overall survival (OS): 6.2 months for quizartinib vs. 4.7 in the chemotherapy group; hazard ratio 0.76,...
Paper Details
Title
Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia
Published Date
Feb 17, 2021
Journal
Volume
62
Issue
7
Pages
1756 - 1760
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History